| Terry Shiao, DPM | |
|
1500 S Central Ave Ste 200, Suite 200, Glendale, CA 91204-3853 | |
| (818) 291-4010 | |
| (818) 291-4058 |
| Full Name | Terry Shiao |
|---|---|
| Gender | Female |
| Speciality | Podiatry |
| Experience | 17 Years |
| Location | 1500 S Central Ave Ste 200, Glendale, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386823607 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213ES0103X | Podiatrist - Foot & Ankle Surgery | E4837 (California) | Primary |
| 213ES0103X | Podiatrist - Foot & Ankle Surgery | EL1711 (California) | Secondary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lakeside Medical Organization A Medical Group Inc | 7618005166 | 62 |
News Archive
In the study, the scientists screened known drugs and identified small molecules that could replace conventional reprogramming genes, which can have dangerous side effects.
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, and muscle, today announced preliminary results from the ACE-031 Phase 1 single dose clinical trial indicating that ACE-031 was safe and well-tolerated at all dose levels and increased lean body mass.
A drug that acts like a growth-promoting protein in the brain reduces degeneration and motor deficits associated with Huntington's disease in two mouse models of the disorder, according to a study appearing November 27 in the Journal of Neuroscience. The findings add to a growing body of evidence that protecting or boosting neurotrophins - the molecules that support the survival and function of nerve cells - may slow the progression of Huntington's disease and other neurodegenerative disorders.
NPR's Julie Rovner fact-checked several of the television ads being run about the health care debate. She found fault with several major ads, including ones sponsored by American Federation of State County and Municipal Employees (AFSCME), the liberal group Americans United for Change, National Republican Campaign Committee, the Progressive Change Campaign Committee, Democracy for America, and the U.S. Chamber of Commerce.
Epilepsy remains one of the most common neurological conditions, affecting one in 26 Americans in their lifetime, with one-third having a form of the condition that resists treatment or effective management. With those statistics in mind, more than 5,200 neurologists, scientists, nurses and health professionals came to Philadelphia December 4-8 for the 2015 American Epilepsy Society Annual Meeting to discuss new discoveries and emerging technologies that can lead to more effective treatment.
› Verified 7 days ago
| Provider Name | Lakeside Medical Organization A Medical Group Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1831426642 PECOS PAC ID: 7618005166 Enrollment ID: O20100505000015 |
News Archive
In the study, the scientists screened known drugs and identified small molecules that could replace conventional reprogramming genes, which can have dangerous side effects.
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, and muscle, today announced preliminary results from the ACE-031 Phase 1 single dose clinical trial indicating that ACE-031 was safe and well-tolerated at all dose levels and increased lean body mass.
A drug that acts like a growth-promoting protein in the brain reduces degeneration and motor deficits associated with Huntington's disease in two mouse models of the disorder, according to a study appearing November 27 in the Journal of Neuroscience. The findings add to a growing body of evidence that protecting or boosting neurotrophins - the molecules that support the survival and function of nerve cells - may slow the progression of Huntington's disease and other neurodegenerative disorders.
NPR's Julie Rovner fact-checked several of the television ads being run about the health care debate. She found fault with several major ads, including ones sponsored by American Federation of State County and Municipal Employees (AFSCME), the liberal group Americans United for Change, National Republican Campaign Committee, the Progressive Change Campaign Committee, Democracy for America, and the U.S. Chamber of Commerce.
Epilepsy remains one of the most common neurological conditions, affecting one in 26 Americans in their lifetime, with one-third having a form of the condition that resists treatment or effective management. With those statistics in mind, more than 5,200 neurologists, scientists, nurses and health professionals came to Philadelphia December 4-8 for the 2015 American Epilepsy Society Annual Meeting to discuss new discoveries and emerging technologies that can lead to more effective treatment.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Terry Shiao, DPM 1500 S Central Ave Ste 200, Suite 200, Glendale, CA 91204-3853 Ph: () - | Terry Shiao, DPM 1500 S Central Ave Ste 200, Suite 200, Glendale, CA 91204-3853 Ph: (818) 291-4010 |
News Archive
In the study, the scientists screened known drugs and identified small molecules that could replace conventional reprogramming genes, which can have dangerous side effects.
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, and muscle, today announced preliminary results from the ACE-031 Phase 1 single dose clinical trial indicating that ACE-031 was safe and well-tolerated at all dose levels and increased lean body mass.
A drug that acts like a growth-promoting protein in the brain reduces degeneration and motor deficits associated with Huntington's disease in two mouse models of the disorder, according to a study appearing November 27 in the Journal of Neuroscience. The findings add to a growing body of evidence that protecting or boosting neurotrophins - the molecules that support the survival and function of nerve cells - may slow the progression of Huntington's disease and other neurodegenerative disorders.
NPR's Julie Rovner fact-checked several of the television ads being run about the health care debate. She found fault with several major ads, including ones sponsored by American Federation of State County and Municipal Employees (AFSCME), the liberal group Americans United for Change, National Republican Campaign Committee, the Progressive Change Campaign Committee, Democracy for America, and the U.S. Chamber of Commerce.
Epilepsy remains one of the most common neurological conditions, affecting one in 26 Americans in their lifetime, with one-third having a form of the condition that resists treatment or effective management. With those statistics in mind, more than 5,200 neurologists, scientists, nurses and health professionals came to Philadelphia December 4-8 for the 2015 American Epilepsy Society Annual Meeting to discuss new discoveries and emerging technologies that can lead to more effective treatment.
› Verified 7 days ago
Dr. Melineh Aslanian, D.P.M. Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 125 E Glenoaks Blvd Ste 104, Glendale, CA 91207 Phone: 818-500-0267 Fax: 818-500-0278 | |
Dr Frank J Garofalo Dpm Inc Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 1101 N Pacific Ave Ste 104, Glendale, CA 91202 Phone: 818-552-5000 Fax: 818-552-2959 | |
Glenoaks Podiatry Group Inc Podiatrist Medicare: Medicare Enrolled Practice Location: 844 West Glenoaks Blvd, Glendale, CA 91202 Phone: 818-500-1888 Fax: 818-500-0695 | |
David Robert Swanson, D.P.M. Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 300 E Glenoaks Blvd, Glendale, CA 91207 Phone: 818-241-6269 | |
Glendale Podiatry Group Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 800 S Central Ave, #302, Glendale, CA 91204 Phone: 818-240-5575 Fax: 818-240-1487 | |
Sarmont Podiatry, Inc. Podiatrist Medicare: Medicare Enrolled Practice Location: 125 E Glenoaks Blvd Ste 104, Glendale, CA 91207 Phone: 818-500-0267 Fax: 818-500-0278 | |
Jittima Jirasetpatana, D.P.M. Podiatrist Medicare: May Accept Medicare Assignments Practice Location: 1510 S Central Ave, Suite 120, Glendale, CA 91204 Phone: 818-242-3668 Fax: 818-242-2425 |